Compare AIRE & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | CELU |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | 123 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 35.2M |
| IPO Year | 2023 | N/A |
| Metric | AIRE | CELU |
|---|---|---|
| Price | $0.27 | $1.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.30 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.1M | 24.3K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $129.06 | N/A |
| Revenue Next Year | $83.72 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.14 | $1.01 |
| 52 Week High | $1.55 | $4.35 |
| Indicator | AIRE | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 25.14 |
| Support Level | $0.22 | N/A |
| Resistance Level | $0.35 | $1.46 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 44.28 | 3.55 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.